Castlight Health Announces Third Quarter 2015 Results
Total Revenue of $19.5 Million, Up 60% Year Over Year
/EINPresswire.com/ -- SAN FRANCISCO, CA--(Marketwired - November 04, 2015) - Castlight Health, Inc. (NYSE: CSLT), the leader in enterprise healthcare management (EHM), today announced results for its third quarter ended September 30, 2015.
"Among the new customers Castlight added during the quarter were four Fortune 500 businesses. We also signed an exciting collaboration with Anthem Inc. to accelerate adoption of Castlight technologies," said Giovanni Colella, M.D., co-founder and chief executive officer of Castlight Health. "We significantly expanded our product leadership with the addition of Castlight Action, a new product that gives benefits leaders simple and effective new ways to proactively identify and connect employees who need care with the benefits that can help them."
Financial Performance for the Three Months Ended September 30, 2015
- Total revenue for the third quarter of 2015 was $19.5 million, an increase of 60% from the third quarter of 2014. Subscription revenue was $18.2 million, an increase of 62% on a year-over-year basis.
- Gross margin for the third quarter of 2015 was 55.5%, compared to a gross margin of 41.4% in the third quarter of 2014. Non-GAAP gross margin for the third quarter of 2015 was 59.3% compared to a non-GAAP gross margin of 44.4% in the third quarter of 2014.
- Operating loss for the third quarter of 2015 was $20.1 million, compared to an operating loss of $20.3 million in the third quarter of 2014. Non-GAAP operating loss for the third quarter of 2015 was $15.9 million, compared to a non-GAAP operating loss of $16.2 million in the third quarter of 2014.
- Net loss per basic and diluted share was $0.21 in the third quarter of 2015, compared to a net loss per basic and diluted share of $0.23 in the third quarter of 2014. The non-GAAP net loss per basic and diluted share for the third quarter of 2015 was $0.17, compared to a net loss per basic and diluted share of $0.18 in the third quarter of 2014. For both GAAP and non-GAAP purposes, the weighted average basic and diluted share count for the third quarter of 2015 was 94.4 million compared to 89.7 million in the third quarter of 2014.
- Total cash, cash equivalents and marketable securities were $147.2 million at the end of the third quarter of 2015. Cash used in operations for the third quarter of 2015 was $14.5 million, compared to $7.5 million used in operations in the third quarter of 2014.
A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures".
Business Outlook
Q4 2015 Guidance: Revenue for the company's fourth quarter is expected to be $20.7 million to $21.0 million. We expect to generate a non-GAAP operating loss in the range of $15.4 million to $16.4 million and a non-GAAP net loss per share of $0.16 to $0.17 based on 95 million weighted average basic and diluted shares outstanding.
Full Year 2015 Guidance: Revenue for the company's full year 2015 is expected to be in the range of $74.7 million to $75.0 million, an increase of 64% year-over-year. Non-GAAP operating loss is expected to be in the range of $65.0 million to $66.0 million. Non-GAAP basic and diluted loss per share is expected to be in the range of $0.68 to $0.70 based on 94 million to 95 million weighted average basic and diluted common shares outstanding.
For both the fourth quarter and the full year 2015, non-GAAP guidance excludes the effects of stock-based compensation expense and capitalization and amortization of internal-use software.
Quarterly Conference Call
Castlight Health will host a conference call to discuss its third quarter 2015 results today at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the company's Investor Relations website at http://ir.castlighthealth.com. In addition, an archive of the webcast can be accessed through the same link. Participants who choose to call in to the conference call can do so by dialing 1-877-201-0168. The conference ID number is 57888376. A replay will be available for one week at 1-855-859-2056, passcode 57897700.
About Castlight Health
Castlight Health, Inc. (NYSE: CSLT) is a leader in Enterprise Healthcare Management. We believe great healthcare builds great business and U.S. enterprises can gain control over the $620 billion spent annually on healthcare, transforming a crippling cost into a strategic business advantage. Recognized as a top 2014 software platform by the HR Technology Conference & Exposition, the Castlight Enterprise Healthcare Cloud enables employers to understand and manage all their healthcare investments while helping employees make the best possible healthcare decisions. Castlight is a great place to work, honored with a Glassdoor Employees' Choice award and recognized by Rock Health for Diversity in Leadership. For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook. Source: Castlight Health.
Non-GAAP Financial Measures
To supplement Castlight Health's financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross margin (loss), non-GAAP operating expense, non-GAAP operating loss, non-GAAP net loss and non-GAAP net loss per share. These non-GAAP financial measures differ from GAAP financial measures in that they exclude stock-based compensation, warrant expense, capitalization and amortization of internal-use software and the associated tax impact of these items, where applicable.
We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company's core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company's historical financial performance.
We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the fourth quarter of 2015 and full year 2015 to comparable GAAP operating loss and net loss per share guidance because we do not provide guidance for stock-based compensation expense and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP operating loss. The factors that may impact our future stock-based compensation expense and capitalization and amortization of internal-use software are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort.
These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP. Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company's financial information in its entirety and not rely on a single financial measure.
Safe Harbor For Forward-Looking Statements
This press release contains forward-looking statements about Castlight Health's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health's fourth quarter and full year projections, our expectations for future performance of our business, market growth and business conditions, future innovation by the company and future developments with respect to the digital healthcare industry. Statements including words such as "anticipate," "believe," "estimate," "will," "continue," "expect," or "future," and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health's documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.
Copyright 2015 Castlight Health, Inc. Castlight Health
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
As of
------------------------
September December
30, 2015 31, 2014
----------- -----------
(unaudited)
Assets
Current assets:
Cash and cash equivalents $ 25,671 $ 17,425
Marketable securities 121,525 175,057
Accounts receivable, net 13,645 11,097
Deferred commissions 3,864 3,675
Prepaid expenses and other current assets 5,134 3,476
----------- -----------
Total current assets 169,839 210,730
Property and equipment, net 6,269 3,630
Marketable securities, noncurrent - 6,220
Restricted cash, noncurrent 1,000 -
Deferred commissions, noncurrent 3,145 2,563
Other assets 4,670 131
----------- -----------
Total assets $ 184,923 $ 223,274
=========== ===========
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 4,057 $ 3,217
Accrued expenses and other current liabilities 4,975 5,791
Accrued compensation 9,457 10,455
Deferred revenue 24,592 20,708
----------- -----------
Total current liabilities 43,081 40,171
Deferred revenue, noncurrent 8,538 6,652
Other liabilities, noncurrent 1,455 261
----------- -----------
Total liabilities 53,074 47,084
Commitments and contingencies
Stockholders' equity 131,849 176,190
----------- -----------
Total liabilities and stockholders' equity $ 184,923 $ 223,274
=========== ===========
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
----------------------- -----------------------
2015 2014 2015 2014
----------- ----------- ----------- -----------
Revenue:
Subscription $ 18,233 $ 11,254 $ 50,417 $ 28,293
Professional services 1,306 955 3,583 2,825
----------- ----------- ----------- -----------
Total revenue 19,539 12,209 54,000 31,118
----------- ----------- ----------- -----------
Cost of revenue:
Cost of subscription (1) 3,081 2,596 8,532 8,223
Cost of professional
services (1) 5,606 4,559 15,581 12,932
----------- ----------- ----------- -----------
Total cost of revenue 8,687 7,155 24,113 21,155
----------- ----------- ----------- -----------
Gross profit 10,852 5,054 29,887 9,963
----------- ----------- ----------- -----------
Operating expenses:
Sales and marketing (1) 16,731 14,760 50,835 46,267
Research and development
(1) 7,868 5,630 21,853 16,633
General and
administrative (1) 6,311 4,944 18,291 13,473
----------- ----------- ----------- -----------
Total operating expenses 30,910 25,334 90,979 76,373
----------- ----------- ----------- -----------
Operating loss (20,058) (20,280) (61,092) (66,410)
Other income, net 51 81 230 154
----------- ----------- ----------- -----------
Net loss $ (20,007) $ (20,199) $ (60,862) $ (66,256)
=========== =========== =========== ===========
Net loss per share, basic
and diluted $ (0.21) $ (0.23) $ (0.65) $ (0.96)
=========== =========== =========== ===========
Weighted-average shares
used to compute basic and
diluted net loss per share 94,409 89,698 93,343 68,960
=========== =========== =========== ===========
---------------------------
1. Includes stock-based compensation expense as follows:
Three Months Ended Nine Months Ended
September 30, September 30,
----------------------- -----------------------
2015 2014 2015 2014
----------- ----------- ----------- -----------
Cost of revenue:
Cost of subscription $ 96 $ 60 $ 196 $ 99
Cost of professional
services 647 306 1,522 726
Sales and marketing 2,058 2,013 5,883 4,339
Research and development 981 561 2,344 1,475
General and administrative 1,177 1,169 3,100 2,963
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
----------------------- -----------------------
2015 2014 2015 2014
----------- ----------- ----------- -----------
Operating activities:
Net loss $ (20,007) $ (20,199) $ (60,862) $ (66,256)
Adjustments to reconcile
net loss to net cash used
in operating activities:
Depreciation 468 340 1,378 944
Stock-based compensation 4,959 4,109 13,045 9,602
Amortization of deferred
commissions 917 875 2,576 3,119
Accretion and
amortization of
marketable securities 299 524 1,126 1,021
Expense related to
warrant - 160 - 2,659
Changes in operating
assets and liabilities:
Accounts receivable (2,597) (886) (2,548) (6,213)
Deferred commissions (1,595) (2,257) (3,346) (3,626)
Prepaid expenses and
other assets 792 (245) (1,026) (1,922)
Accounts payable (542) (191) 716 193
Accrued expenses and
other liabilities 1,429 3,956 (1,740) 2,753
Deferred revenue 1,367 6,356 5,770 14,633
----------- ----------- ----------- -----------
Net cash used in operating
activities (14,510) (7,458) (44,911) (43,093)
----------- ----------- ----------- -----------
Investing activities:
Restricted cash - - (1,000) 101
Investment in related
party (1,000) - (4,125) -
Purchase of property and
equipment (1,806) (431) (3,499) (1,398)
Purchase of marketable
securities (67,366) (48,213) (86,324) (210,388)
Sales of marketable
securities - - 5,000 13,000
Maturities of marketable
securities 78,466 45,765 140,019 53,765
----------- ----------- ----------- -----------
Net cash provided by (used
in) investing activities 8,294 (2,879) 50,071 (144,920)
----------- ----------- ----------- -----------
Financing activities:
Proceeds from the
exercise of stock
options 354 300 3,180 1,928
Payments of deferred
financing costs - - (94) -
Net proceeds from initial
public offering - - - 186,162
----------- ----------- ----------- -----------
Net cash provided by
financing activities 354 300 3,086 188,090
----------- ----------- ----------- -----------
Net increase (decrease) in
cash and cash equivalents (5,862) (10,037) 8,246 77
Cash and cash equivalents
at beginning of period 31,533 35,268 17,425 25,154
----------- ----------- ----------- -----------
Cash and cash equivalents
at end of period $ 25,671 $ 25,231 $ 25,671 $ 25,231
=========== =========== =========== ===========
CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)
Three Months Ended Nine Months Ended
-------------------------------- ---------------------
September September September September
30, June 30, 30, 30, 30,
2015 2015 2014 2015 2014
---------- ---------- ---------- ---------- ----------
Gross profit:
GAAP gross profit
subscription $ 15,152 $ 14,346 $ 8,658 $ 41,885 $ 20,070
GAAP gross margin
subscription 83.1% 83% 76.9% 83.1% 70.9%
Stock-based
compensation
expense 96 67 60 196 99
Amortization of
internal-use
software 24 24 - 72 -
---------- ---------- ---------- ---------- ----------
Non-GAAP gross
profit
subscription $ 15,272 $ 14,437 $ 8,718 $ 42,153 $ 20,169
========== ========== ========== ========== ==========
Non-GAAP gross
margin
subscription 83.8% 83.6% 77.5% 83.6% 71.3%
GAAP gross loss
professional
services $ (4,300) $ (4,090) $ (3,604) $(11,998) $(10,107)
GAAP gross loss
percentage
professional
services (329)% (332)% (377)% (335)% (358)%
Stock-based
compensation
expense 647 450 306 1,522 726
Capitalization
of internal-use
software (33) - - (33) -
---------- ---------- ---------- ---------- ----------
Non-GAAP gross
loss professional
services $ (3,686) $ (3,640) $ (3,298) $(10,509) $ (9,381)
=======================================================
Non-GAAP gross
loss percentage
professional
services (282)% (295)% (345)% (293)% (332)%
GAAP gross profit $ 10,852 $ 10,256 $ 5,054 $ 29,887 $ 9,963
GAAP gross margin 55.5% 55.4% 41.4% 55.3% 32.0%
Impact of non-
GAAP
adjustments 734 541 366 1,757 825
---------- ---------- ---------- ---------- ----------
Non-GAAP gross
profit $ 11,586 $ 10,797 $ 5,420 $ 31,644 $ 10,788
========== ========== ========== ========== ==========
Non-GAAP gross
margin 59.3% 58.3% 44.4% 58.6% 34.7%
Operating expense:
GAAP sales and
marketing $ 16,731 $ 17,641 $ 14,760 $ 50,835 $ 46,267
Expense related
to warrant - - (160) - (2,659)
Stock-based
compensation
expense (2,058) (2,074) (2,013) (5,883) (4,339)
---------- ---------- ---------- ---------- ----------
Non-GAAP sales and
marketing $ 14,673 $ 15,567 $ 12,587 $ 44,952 $ 39,269
========== ========== ========== ========== ==========
GAAP research and
development $ 7,868 $ 7,391 $ 5,630 $ 21,853 $ 16,633
Stock-based
compensation
expense (981) (730) (561) (2,344) (1,475)
Capitalization
of internal-use
software 841 513 162 1,636 162
---------- ---------- ---------- ---------- ----------
Non-GAAP research
and development $ 7,728 $ 7,174 $ 5,231 $ 21,145 $ 15,320
========== ========== ========== ========== ==========
GAAP general and
administrative $ 6,311 $ 6,517 $ 4,944 $ 18,291 $ 13,473
Stock-based
compensation
expense (1,177) (896) (1,169) (3,100) (2,963)
---------- ---------- ---------- ---------- ----------
Non-GAAP general
and
administrative $ 5,134 $ 5,621 $ 3,775 $ 15,191 $ 10,510
========== ========== ========== ========== ==========
GAAP operating
expense $ 30,910 $ 31,549 $ 25,334 $ 90,979 $ 76,373
Impact of non-
GAAP
adjustments (3,375) (3,187) (3,741) (9,691) (11,274)
---------- ---------- ---------- ---------- ----------
Non-GAAP operating
expense $ 27,535 $ 28,362 $ 21,593 $ 81,288 $ 65,099
Operating loss:
GAAP operating
loss $(20,058) $(21,293) $(20,280) $(61,092) $(66,410)
Impact of non-
GAAP
adjustments 4,109 3,728 4,107 11,448 12,099
---------- ---------- ---------- ---------- ----------
Non-GAAP operating
loss $(15,949) $(17,565) $(16,173) $(49,644) $(54,311)
========== ========== ========== ========== ==========
Net loss and net
loss per share:
GAAP net loss $(20,007) $(21,212) $(20,199) $(60,862) $(66,256)
Total pre-tax
impact of non-
GAAP
adjustments 4,109 3,728 4,107 11,448 12,099
Income tax
impact of non-
GAAP
adjustments - - - - -
---------- ---------- ---------- ---------- ----------
Non-GAAP net loss $(15,898) $(17,484) $(16,092) $(49,414) $(54,157)
========== ========== ========== ========== ==========
Basic and Diluted
net loss per
share
GAAP $ (0.21) $ (0.23) $ (0.23) $ (0.65) $ (0.96)
========== ========== ========== ========== ==========
Non-GAAP $ (0.17) $ (0.19) $ (0.18) $ (0.53) $ (0.79)
========== ========== ========== ========== ==========
Shares used in
basic and diluted
net loss per
share computation 94,409 93,804 89,698 93,343 68,960
========== ========== ========== ========== ==========
Investor Contact:
Charles Butler
ir@castlighthealth.com
415-829-1400
Media Contact:
Jim Rivas
press@castlighthealth.com
415-515-8780
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
